SCHEMBL30355658

SCHEMBL30355658

CCC1(CC)CC(=O)c2cc(-c3nc(-c4ccc5nonc5c4)no3)ccc2O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 10/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ S1PR3 Q99500 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ NPC1 O15118 4/20 0.34
▸ RAB9A P51151 4/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MAPT P10636 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23524184 1.00 S1PR1 (0.39) S1PR1SMN1; SMN2CNR1CNR2KCNH2
SCHEMBL23523716 0.85 NPC1 (0.43) SMN1; SMN2GAANPC1RAB9AKDM4E
SCHEMBL30355571 0.85 NPC1 (0.43) SMN1; SMN2GAANPC1RAB9AKDM4E
SCHEMBL23523752 0.85 S1PR1 (0.38) S1PR1SMN1; SMN2CNR1CNR2S1PR3
SCHEMBL23524350 0.85 S1PR1 (0.39) S1PR1SMN1; SMN2CNR1CNR2GAA
SCHEMBL30355706 0.85 S1PR1 (0.39) S1PR1SMN1; SMN2CNR1CNR2GAA
SCHEMBL23523985 0.85 CNR1 (0.38) S1PR1SMN1; SMN2CNR1CNR2S1PR3
SCHEMBL23524003 0.85 S1PR1 (0.47) S1PR1SMN1; SMN2S1PR3GAANPC1
SCHEMBL23523721 0.85 NPC1 (0.38) S1PR1SMN1; SMN2CNR1CNR2S1PR3
SCHEMBL23523871 0.85 MAPT (0.43) S1PR1SMN1; SMN2CNR1CNR2S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same TREVENA, INC. (US) 2024-02-27 — — US disclosed
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME TREVENA, INC. 2023-07-27 — — US disclosed
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME TREVENA, INC. 2023-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME S1PR1, S1PR2, S1PR3 S1PR1 1/4885SMN1; SMN2 1320/4885CNR1 20/4885
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME S1PR1, S1PR2, S1PR3 S1PR1 1/4885SMN1; SMN2 619/4885CNR1 10/4885
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same S1PR1, S1PR2, S1PR3 S1PR1 1/4885SMN1; SMN2 1320/4885CNR1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback